SCI Pharmtech Stock

SCI Pharmtech Equity

The The Equity of SCI Pharmtech (4119.TW) as of Aug 9, 2026 is 5.39 B TWD. In the previous year, The Equity was 5.48 B TWD — a change of -1.51% (lower).

Equity

5.39 BTWD

YoY

-1.51%

Last updated:

In 2026, SCI Pharmtech's equity was 5.39 B TWD, a -1.51% increase from the 5.48 B TWD equity in the previous year.

Access this data via the Eulerpool API

SCI Pharmtech Stock analysis

What does SCI Pharmtech do? SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SCI Pharmtech's Equity

SCI Pharmtech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SCI Pharmtech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SCI Pharmtech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SCI Pharmtech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SCI Pharmtech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SCI Pharmtech stock

The Equity of SCI Pharmtech is 5.39 B TWD in 2026.

The Equity of SCI Pharmtech changed from 5.48 B TWD to 5.39 B TWD, representing a -1.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity SCI Pharmtech since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's SCI Pharmtech historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCI Pharmtech

All Key Metrics — SCI Pharmtech